Changes in Serum Interleukin-8 Levels Predict Response to Immune Checkpoint Inhibitors Immunotherapy in Unresectable Hepatocellular Carcinoma Patients
Jiao Zhang,Yi Yin,Jiliang Tang,Yingrong Zhang,Yanan Tian,Fengkai Sun
DOI: https://doi.org/10.2147/jir.s460931
IF: 4.5
2024-05-25
Journal of Inflammation Research
Abstract:Jiao Zhang, 1, 2 Yi Yin, 3, 4 Jiliang Tang, 5 Yingrong Zhang, 1, 2 Yanan Tian, 1, 2 Fengkai Sun 1, 2, 6 1 Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China; 2 Department of Gastroenterology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, People's Republic of China; 3 Department of Paediatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China; 4 Department of Paediatrics, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, People's Republic of China; 5 Emergency Department, Rizhao Central Hospital, Rizhao, People's Republic of China; 6 College of Acupuncture and Massage, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China Correspondence: Fengkai Sun, Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jingwu Road 324&num, Jinan, 250021, People's Republic of China, Tel +86-531-68776902, Fax +86-531-68776072, Email ; Background: Effective biomarkers are needed to predict the efficacy of immune checkpoint inhibitors (ICIs) therapy in hepatocellular carcinoma (HCC). We evaluated the early changes in serum interleukin-8 (IL-8) levels as a biomarker of response to ICIs in patients with unresectable HCC. Methods: Eighty patients who received ICIs therapy alone or in combination with other treatments for unresectable HCC were included. Serum was collected at baseline and 2– 4 weeks after the first dose. Serum IL-8 levels were measured using by ELISA. Results: In the progressive disease (PD) group, serum IL-8 levels increased significantly before the second dose of ICIs therapy compared with baseline levels ( P < 0.001). Early changes in serum IL-8 levels were significantly associated with the response to ICIs therapy ( P 8.1% indicated the uselessness of ICIs immunotherapy in patients with unresectable HCC. Patients with increases in serum IL-8 levels > 8.1% had significantly shorter overall survival (OS) and progression-free survival (PFS) than those with increases in serum IL-8 levels ≤ 8.1% ( P 8.1% were independent prognosticators of worse OS ( P = 0.003) and PFS ( P < 0.001). Conclusion: Early changes in serum IL-8 levels, measured only 2– 4 weeks after starting therapy, could predict the response to ICIs therapy, as well as OS and PFS of patients with unresectable HCC. Increases in serum IL-8 levels > 8.1% indicated the uselessness of ICIs immunotherapy and predicted worse OS and PFS. Keywords: interleukin-8, immune checkpoint inhibitor, response, serum biomarker, hepatocellular carcinoma As the major primary tumor in the liver, hepatocellular carcinoma (HCC) ranks sixth as most frequently diagnosed cancer and fourth as most common cause of cancer-related deaths worldwide. 1 Curative therapy remains limited to a small subset of patients because approximately 80% of patients with HCC are already at an advanced stage at the time of diagnosis. 2 In recent years, the landscape of systemic therapy for advanced HCC has changed dramatically with the emergence of immune checkpoint inhibitors (ICIs). The objective response rate (ORR) of patients who receive anti-PD-1 therapy as monotherapy for advanced HCC has been reported to be 15–20%. 3,4 Recently, a combination of atezolizumab, an anti-PD-L1 mAb, and bevacizumab, an anti-vascular endothelial growth factor mAb, has been approved as the first-line treatment for unresectable HCC, considering that the combination outperformed sorafenib in terms of survival and response. 5,6 Although the clinical progress of ICIs for HCC has been accelerating, only some patients benefit from immunotherapy. Besides, about 25% of patients develop grade 3–4 immune-related adverse events. 7 Therefore, exploring biomarkers that predict the clinical response to immunotherapy can potentially improve patient selection, maximize clinical benefits, and avoid unnecessary toxicity. Studies to identify possible predictive biomarkers for immunotherapy in HCC have recently begun. 7 Interleukin-8 (IL-8), a member of the CXC chemokine family, is secreted by the tumor and stromal cells in various tumor types. It is -Abstract Truncated-
immunology